PXD043261 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Ancistrocladinium A induces cell death in drug-resistant myeloma cells via targeting transcription and RNA splicing machinery and ATF4-dependent apoptotic pathway: a promising candidate as a drug for multiple myeloma |
Description | N,C-coupled naphthylisoquinoline alkaloids like the natural product ancistrocladinium A, was known for its strong antiprotozoal activity, but had never explored for its antitumor activity. We found the alkaloid to be a very efficient anti-myeloma agent in various cell lines, including proteasome inhibitor-resistant cell lines and patient's primary CD138+ myeloma cells either alone or in combination approaches with the compounds carfilzomib or panobinostat. To gain further insight, we used an MS-based approach with the biotinylated derivative of Ancistrocladinium A, leading to an enrichment of RNA splicing associated proteins. We validated alternative pre-mRNA splicing by analyzing RNA gene expression and splicing using the human Clariom D gene array after treatment of INA-6 cells with the alkaloid. Important pathways with altered RNA expression levels included RNA processing, transcription and splicing, and the ribonucleoprotein complex. Pathways with altered RNA splicing included PSMB5 target genes and, therefore, a driver of unfolded protein response (UPR) along with transcription-associated and cell cycle-associated genes. Furthermore, we confirmed the splicing-induced protein expression of activating tran-scription factor 4 (ATF4), a key regulator of UPR. Finally, histone 2A (H2A) phosphorylation and PARP-1 cleavage as an indicator of apoptosis indicator was also detected. Taken together, an-cistrocladinium A can be considered as a potent agent against PI-resistance in MM either alone or in combination with clinically approved drugs. |
HostingRepository | PRIDE |
AnnounceDate | 2023-10-24 |
AnnouncementXML | Submission_2023-10-24_13:28:51.392.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | DanielaBruennert |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | No PTMs are included in the dataset |
Instrument | Orbitrap Fusion |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2023-06-24 06:18:41 | ID requested | |
⏵ 1 | 2023-10-24 13:28:52 | announced | |
2 | 2023-11-14 09:11:50 | announced | 2023-11-14: Updated project metadata. |
3 | 2024-10-22 06:12:42 | announced | 2024-10-22: Updated project metadata. |
Publication List
Br, ü, nnert D, Seupel R, Goyal P, Bach M, Schraud H, Kirner S, K, ö, ster E, Feineis D, Bargou RC, Schlosser A, Bringmann G, Chatterjee M, Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate. Pharmaceuticals (Basel), 16(8):(2023) [pubmed] |
Keyword List
submitter keyword: Ancistrocladinium A, carfilzomib, RNA splicing, panobinostat, nanoLC-MS/MS,Multiple Myeloma, proteasome inhibitor resistance |
Contact List
ManikChatterjee |
contact affiliation | University Hospital Wuerzburg Comprehensive Cancer Center Mainfranken Translational Oncology |
contact email | Chatterjee_M@ukw.de |
lab head | |
DanielaBruennert |
contact affiliation | Universitätsklinikum Würzburg |
contact email | Bruennert_d@ukw.de |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/10/PXD043261 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD043261
- Label: PRIDE project
- Name: Ancistrocladinium A induces cell death in drug-resistant myeloma cells via targeting transcription and RNA splicing machinery and ATF4-dependent apoptotic pathway: a promising candidate as a drug for multiple myeloma